Skip to main content
Atrás
RMD logo

ResMed Inc.

Calidad de datos: 100%
RMD
NYSE Healthcare Medical - Instruments & Supplies
$228.19
▲ $0.22 (0.10%)
Cap. Mercado: 33.31B
Rango del Día
$224.92 $231.45
Rango de 52 Semanas
$199.92 $293.81
Volumen
1,000,692
Promedio 50D / 200D
$252.88 / $260.16
Cierre Anterior
$227.97

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E 23.8 0.4
P/B 5.6 2.9
ROE % 25.9 3.9
Net Margin % 27.2 3.8
Rev Growth 5Y % 12.6 10.0
D/E 0.1 0.2

Precio Objetivo de Analistas

Hold
$295.88 +29.7%
Low: $265.00 High: $345.00
P/E Futuro
20.6
EPS Futuro
$11.05
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
5.6 B

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $16.20
$15.91 – $16.44
 7.8 B 4
FY2029 $14.38
$14.13 – $14.59
 7 B 3
FY2028 $13.43
$12.12 – $14.29
 6.5 B 9

Puntos Clave

Revenue grew 12.64% annually over 5 years — strong growth
Earnings grew 37.20% over the past year
ROE of 25.86% indicates high profitability
Net margin of 27.22% shows strong profitability
Debt/Equity of 0.14 — conservative balance sheet
Generating 1.66B in free cash flow

Crecimiento

Revenue Growth (5Y)
12.64%
Revenue (1Y)9.84%
Earnings (1Y)37.20%
FCF Growth (3Y)72.37%

Calidad

Return on Equity
25.86%
ROIC18.53%
Net Margin27.22%
Op. Margin32.75%

Seguridad

Debt / Equity
0.14
Current Ratio3.44
Interest Coverage133.66

Valoración

P/E Ratio
23.78
P/B Ratio5.58
EV/EBITDA19.55
Dividend Yield0.01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 9.84% Revenue Growth (3Y) 10.39%
Earnings Growth (1Y) 37.20% Earnings Growth (3Y) 24.92%
Revenue Growth (5Y) 12.64% Earnings Growth (5Y) 31.08%
Profitability
Revenue (TTM) 5.15B Net Income (TTM) 1.40B
ROE 25.86% ROA 17.14%
Gross Margin 59.36% Operating Margin 32.75%
Net Margin 27.22% Free Cash Flow (TTM) 1.66B
ROIC 18.53% FCF Growth (3Y) 72.37%
Safety
Debt / Equity 0.14 Current Ratio 3.44
Interest Coverage 133.66 Dividend Yield 0.01%
Valuation
P/E Ratio 23.78 P/B Ratio 5.58
P/S Ratio 6.47 PEG Ratio 0.72
EV/EBITDA 19.55 Dividend Yield 0.01%
Market Cap 33.31B Enterprise Value 32.95B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5.15B 4.69B 4.22B 3.58B 3.20B
Net Income 1.40B 1.02B 897.56M 779.44M 474.51M
EPS (Diluted) 9.51 6.92 6.09 5.30 3.24
Gross Profit 3.05B 2.66B 2.36B 2.02B 1.84B
Operating Income 1.69B 1.32B 1.13B 1.00B 903.68M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8.17B 6.87B 6.75B 5.10B 4.73B
Total Liabilities 2.21B 2.01B 2.62B 1.74B 1.84B
Shareholders' Equity 5.97B 4.86B 4.13B 3.36B 2.89B
Total Debt 851.81M 873.94M 1.58B 917.55M 793.72M
Cash & Equivalents 1.21B 238.36M 227.89M 273.71M 295.28M
Current Assets 3.51B 2.36B 2.37B 1.93B 1.57B
Current Liabilities 1.02B 910.66M 758.53M 689.30M 911.77M

Puntuaciones de Estrategias

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#932 of 1052
24
Custom Capital Light Compounder
#187 of 218
25
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#203 of 332
46
Custom Balanced Risk
#94 of 151
43
Custom Lower Risk
#120 of 140
34

Actividad Reciente

Entró Cash Flow Compounder
Mar 25, 2026
Entró Capital Light Compounder
Mar 25, 2026
Entró Balanced Risk
Mar 25, 2026
Entró Lower Risk
Mar 25, 2026
Entró Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026